DexCom, Inc.

DXCM

CIK 0001093557 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$1.26B
↑+13.1% +$146Mvs FY2024 (Q4)
Operating Income
$323M
↑+71.0% +$134Mvs FY2024 (Q4)
Net Income
$267M
↑+76.2% +$116Mvs FY2024 (Q4)
Gross Profit
$793M
↑+20.9% +$137Mvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Strong
78/100
  • Profitability
    100ROIC 28.9% (10% = solid, 20%+ = moat)
  • Liquidity
    69Current Ratio 1.88 (above 1.5 = solid)
  • Leverage
    98D/E 0.03 (under 0.5 = conservative)
  • Efficiency
    41Asset Turnover 0.73x (1.0+ = capital-efficient)
  • Growth
    60Revenue YoY +13.1% (10% = solid, 25%+ = elite)
  • Margin Trend
    100Op Margin 25.6% · trend +4.5pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

DCF intrinsic value

DCF intrinsic value

two-stage Gordon model

Project DXCM's free cash flow forward, discount back at your hurdle rate, divide by diluted shares. Edit the assumptions to see how sensitive the intrinsic value is.

25%

Trailing 3-yr CAGR was 52.3%

10%

10% is a common all-equity benchmark for US large-caps

2.5%

Should be ≤ long-run GDP growth (~2.5% nominal)

5

5-year explicit projection + perpetuity terminal

Intrinsic value per share
$88.61
Total enterprise IV
$35.93B
Diluted shares
0.41B
Terminal PV
$27.90B (78% of total)
Year-5 FCF
$3.29B
YearProjected FCFDiscounted PV
+1$1.35B$1.22B
+2$1.68B$1.39B
+3$2.10B$1.58B
+4$2.63B$1.80B
+5$3.29B$2.04B
Terminal$44.93B$27.90B

DCF outputs are HIGHLY sensitive to growth + WACC assumptions. A 1pp WACC change can shift IV by 20%+. Use this as a sanity-check vs market price, not a target — and always cross-check the underlying FCF source (EDGAR cashflow statement, latest annual). Margin of safety convention: 30-50% discount to IV before buying.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$364M
investment in PP&E
Stock buybacks (TTM)
$313M
share count reduction
Stock-based comp (TTM)
$160M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$6.34B
everything owned
Total liabilities
$3.59B
everything owed
Stockholders' equity
$2.75B
shareholder claim
Net debt
$-915M
Net cash position ($915M)

Recent performance · 64 quarters

Revenue↑+13.1% +$146M
$1.26B
Net Income↑+76.2% +$116M
$267M
Free Cash Flow↑+8.7% +$15M
$192M
Operating Margin↑+8.7pts
25.6%

Drill down